comparemela.com

Quest Pharmatech News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Focal Therapy for Prostate Cancer Therapeutics MarketProjected to Garner Significant Revenues by 203

Focal Therapy for Prostate Cancer Therapeutics Market by Type, by End User (Hospitals & Specialty Clinics, Cancer Treatment Centers), and by Region – Global Share and Forecast to 2033

Quest PharmaTech (CVE:QPT) Hits New 1-Year Low at $0 02

Quest PharmaTech Inc. (CVE:QPT – Get Free Report)’s share price reached a new 52-week low during trading on Wednesday . The company traded as low as C$0.02 and last traded at C$0.02, with a volume of 7000 shares. The stock had previously closed at C$0.03. Quest PharmaTech Price Performance The company has a quick ratio […]

Oregovomab Phase III Clinical Study fails futility analysis; Data Safety Monitoring Board Recommends Overall Survival Follow Up for Potential Late Immune Effects and Clinical Benefits

Oregovomab Phase III Clinical Study fails futility analysis; Data Safety Monitoring Board Recommends Overall Survival Follow Up for Potential Late Immune Effects and Clinical Benefits
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Quest PharmaTech Inc Receives Recommendations from the Data Safety Monitoring Board to Discontinue Oregovomab Phase III Clinical Study

Quest PharmaTech Inc. announced that it has received information that the Phase III clinical trial of oregovomab for the treatment of Ovarian Cancer, sponsored by CanariaBio Inc. , has received.

Quest PharmaTech (CVE:QPT) Hits New 52-Week Low at $0 05

Quest PharmaTech Inc. (CVE:QPT – Get Free Report) reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as C$0.05 and last traded at C$0.05, with a volume of 81844 shares trading hands. The stock had previously closed at C$0.05. Quest PharmaTech Price Performance The company has a debt-to-equity […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.